Should I Buy CASI? CASI 2026 Analysis

Should You Buy CASI Pharmaceuticals Inc (CASI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.990

1 Day change

-1.00%

52 Week Range

3.090

Analysis Updated At

2026/01/28

CASI Pharmaceuticals (CASI) is not a good buy right now for a Beginner long-term investor with $50,000–$100,000. The company’s latest quarter shows sharp revenue contraction and margin deterioration, there are no near-term news catalysts, and there are no Intellectia “strong buy” signals today. While the MACD has turned mildly positive, it’s not enough to outweigh weakening fundamentals and very high implied volatility that signals elevated uncertainty.

Technical Analysis

Price is $0.97, sitting just below the pivot (1.001). Momentum is modestly improving: MACD histogram is positive (0.0108) and expanding, which suggests short-term bullish pressure. RSI(6) at ~64.7 is neutral-to-slightly-warm (not overbought). Moving averages are converging, indicating no strong established trend yet (more like a stabilization/inflection than a clear uptrend). Key levels: support S1 ~0.925 then S2 ~0.879; resistance R1 ~1.077 then R2 ~1.123. The pattern-based forecast provided points to mild downside bias over 1 week (-3.13%) and 1 month (-5.86%), which weakens the case for an impatient entry. Intellectia Proprietary Trading Signals: - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options sentiment is hard to trust due to extremely low activity (today’s total volume 2 contracts) and zero puts outstanding/zero put volume, which mechanically forces put/call ratios to 0. Implied volatility is exceptionally elevated (30D IV ~910.84, IV percentile 98, IV rank ~90), signaling the market is pricing in very large potential moves and elevated uncertainty—typically not attractive for a beginner long-term buy-and-hold decision.

Technical Summary

Sell

Buy

Positive Catalysts

Technical momentum has improved slightly (MACD turning positive). Net loss and EPS improved YoY (loss narrowing), which can be a small positive if the trend continues. No insider or hedge fund trend flags (neutral).

Neutral/Negative Catalysts

No recent news catalyst in the last week. Latest quarter shows severe revenue decline (-60.54% YoY) and gross margin deterioration (-55.77% YoY), which is a major fundamental negative for long-term confidence. Extremely high implied volatility suggests the market expects instability. Pattern-based outlook provided indicates downside drift over the next week/month. No supportive Intellectia buy signals today.

Financial Performance

Latest reported quarter: 2025/Q3. Revenue fell to $3.075M (-60.54% YoY), indicating meaningful top-line contraction. Net income improved YoY to -$10.883M (loss narrowed by 29.64% YoY) and EPS improved to -$0.68 (+23.64% YoY), but the business remains loss-making. Gross margin dropped to 22.96% (-55.77% YoY), showing profitability pressure even on reduced sales—this is the most concerning trend for long-term holders.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target trend data was provided, so there’s no clear evidence of Wall Street upgrades, target raises, or improving consensus. With the available dataset, the practical ‘pros vs cons’ view leans negative: pros are limited to modest technical stabilization and narrowing losses; cons are steep revenue/margin deterioration and very high uncertainty signaled by IV. Political/congress trading: no recent data available in the last 90 days.

1 Analyst Rating

Wall Street analysts forecast CASI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CASI is 4 USD with a low forecast of 4 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.000

Low

Averages

High

Current: 1.000

Low

Averages

High

HC Wainwright & Co.

Sean Lee

Strong Buy

Maintains

$6 → $4

AI Analysis

2025-04-09

Reason